Patents by Inventor Kenneth A. Thomas

Kenneth A. Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5312911
    Abstract: Mutant human acidic fibroblast growth factor proteins are recombinantly produced having replaced cysteine residues with amino acids incapable of disulfide bond formation. The recombinantly produced mutant human acidic fibroblast growth factor proteins have improved biological activity in the absence of heparin when compared to wild-type recombinant human acidic fibroblast growth factor.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: May 17, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth A. Thomas, David L. Linemeyer
  • Patent number: 5223483
    Abstract: Mutant human acidic fibroblast growth factor proteins are recombinantly produced having replaced cysteine residues with amino acids incapable of disulfide bond formation. The recombinantly produced mutant human acidic fibroblast growth factor proteins have improved biological activity in the absence of heparin when compared to wild-type recombinant human acidic fibroblast growth factor.
    Type: Grant
    Filed: August 28, 1992
    Date of Patent: June 29, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth A. Thomas, David L. Linemeyer
  • Patent number: 4444760
    Abstract: Acidic brain fibroblast growth factor isolated from bovine brain, is purified by a particular combination of protein purification techniques. The product is useful in the promotion of cell division (mitogenesis) such as in the promotion of wound healing.
    Type: Grant
    Filed: June 17, 1983
    Date of Patent: April 24, 1984
    Assignee: Merck & Co., Inc.
    Inventor: Kenneth A. Thomas, Jr.